All antiretroviral therapy articles
-
NewsUC San Diego receives $12.3 million grant to study the intersection of HIV and methamphetamine use
A newly funded programme aims to use a multidisciplinary approach focused on improving the clinical care and brain health of people with HIV who also have an active methamphetamine use disorder.
-
NewsTriple-dose regimen may permanently clear HIV in infected newborns
New research suggests a one-time regimen of therapies given to newborns within three days of birth could permanently clear HIV infection.
-
NewsBioactive metabolite boosts HIV treatment response, reverses gut dysfunction
Scientists have identified a naturally occurring metabolite that repairs gut damage caused by HIV infection and significantly improves the effectiveness of antiretroviral therapy in the nonhuman primate model of HIV/AIDS.
-
NewsA new HIV vaccine study reveals new hope—and new challenges—for aging patients
A new clinical trial demonstrates that novel vaccines can significantly boost T cells targeting and could contribute to curative approaches against HIV.
-
NewsHIV treatment reduces accelerated biological ageing by nearly four years, landmark study shows
A major study presented at ESCMID Global 2026 has found that antiretroviral therapy (ART) reduces accelerated biological ageing in people with HIV (PWH) by nearly four years, a finding that could transform how clinicians monitor HIV treatment and long-term health outcomes.
-
NewsSpecific patterns of CD39 expression on T-cells of HIV/HCV coinfected patients receiving antiretroviral therapy
Researchers demonstrated that CD4+ T-cells act as the main regulators of purinergic signals in HIV/HCV coinfected and healthy individuals. At the same time, the proportion of CD4+ T-cells involved in the control of purinergic signaling was increased in HIV/HCV coinfected patients compared with healthy subjects.
-
NewsNew tool reveals the secrets of HIV-infected cells
Scientists have developed a novel tool—named HIV-seq—for profiling the features of rare HIV-infected cells from people with HIV. Using the new tool, they’ve found key differences in people’s HIV-infected cells before versus after starting antiretroviral therapy.
-
NewsNew guideline on pre-exposure and postexposure HIV prevention
Multiple pre-exposure (PrEP) and postexposure (PEP) treatments are now available to prevent HIV infection. An updated Canadian guideline contains 31 recommendations and 10 good practice statements to help clinicians and other health care professionals offer these options to patients.
-
NewsNew study identifies key mechanism driving HIV-associated immune suppression
Using humanized mouse models and blood samples from people living with HIV, resarchers found that reducing overactive plasmacytoid dendritic cells helped restore antiviral T cell function and shrink the viral reservoir.
-
NewsLow-dose cannabis compound reduces side effects of HIV treatment
Long-term, low doses of THC mitigate many harmful side effects and inflammation caused by HIV and antiretroviral therapy (ART). Benefits included increased production of serotonin, while inflammation, cholesterol and harmful secondary bile acids were all reduced.
-
NewsNew study highlights gaps in HPV-related cancer prevention for people living with HIV
A new study reveals gaps in knowledge surrounding the prevention of HPV-related cancers in people living with HIV and outlines future research priorities. It highlights existing disparities in healthcare for this vulnerable population.
-
NewsStudy says new drug shows promise in clearing HIV from brain
An experimental drug originally developed to treat cancer may help clear HIV from infected cells in the brain, according to a new study.
-
NewsLong-acting HIV treatment demonstrates efficacy in people with challenges taking daily medicine as prescribed
Long-acting antiretroviral therapy (ART) with cabotegravir and rilpivirine was superior in suppressing HIV replication compared to daily oral ART in people who had been unable to maintain viral suppression through an oral daily regimen, according to interim data from a randomized trial. Source: NIAID Colorized transmission electron micrograph ...
-
NewsResearchers pinpoint most likely source of HIV rebound infection
Researchers used genetic sequencing techniques on the nonhuman primate version of HIV to identify that lymph nodes in the abdomen are the main source of rebound infection after the first week of stopping antiretroviral treatment.
-
NewsStudy uncovers mediators of persistent HIV viremia
Researchers examining people with non-suppressible HIV viremia (NSV) despite receiving antiretroviral therapy (ART) have found large reservoirs of proviruses inserted into transcriptionally active regions of immune cell genomes.
-
NewsDigital test directly measures HIV viral load
Researchers have developed a time and cost-efficient digital assay that can directly measure the presence of HIV in a single drop of blood.